What Does Tirzepatide Cost With and Without Insurance? This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Tirzepatide is sold under the brand names Mounjaro and Zepbound. This diabetes ...
Transforming US drug access and production: MFN pricing deals and historic manufacturing investments
In November 2025, US President Donald Trump announced transformative actions to lower prescription drug costs and secure the ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Researchers projected health care savings of $3.47 ...
Among all antiobesity medications, the incremental cost-effectiveness ratios were $197,023 and $467,676 per quality-adjusted life-year for tirzepatide and semaglutide, respectively. HealthDay News — ...
Zacks Investment Research on MSN
LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website
Eli Lilly LLY announced that it has lowered the price of single-dose vials of its blockbuster obesity drug, Zepbound (tirzepatide), purchased through the direct-to-consumer (DTC) platform LillyDirect.
Tirzepatide and Semaglutide Improve Weight Loss, Cardiovascular Conditions, but Deemed Too Expensive
Tirzepatide and semaglutide, while effective, are not cost-effective due to high prices, negating healthcare savings. Combining antiobesity medications with lifestyle modification improves health ...
Please provide your email address to receive an email when new articles are posted on . Beginning in 2026, prices for 10 drugs will be reduced for Medicare Part D recipients, according to a CMS press ...
The Mumbai-based drugmaker, in a regulatory filing, said it has the rights to distribute and promote Yurpeak, the second anti ...
Tirzepatide, a breakthrough medication for weight loss and diabetes management, has gained significant popularity in South Africa. However, with its growing demand comes the challenge of finding the ...
Tirzepatide showed superior weight loss efficacy over semaglutide in a phase 3b trial, achieving primary and secondary endpoints. Tirzepatide is the only FDA-approved dual GIP and GLP-1 receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results